Mentioned in ?
References in periodicals archive ?
Bristol-Myers Squibb, Novartis, Celgene, Roche, Pfizer, Alexion, Sanofi, Vertex, GlaxoSmithKline, Merck are the top players fetching profits from wealthy orphan drug market.
This report provides analysis of this sector and includes brands that have gained orphan drug approval from the FDA, as well as Phase III pipeline candidates that have gained orphan drug designation from the FDA.
Since the Orphan Drug Act was passed by Congress in 1982, more than 200 drugs and biological products have been brought to market, Cruzan said.
In a bigger view, orphan drug segment is expected to grow several folds in coming years due to several favorable factors.
Our MPS-VI program builds on BioMarin's expertise in the development of enzyme replacement therapies, and positions us now with two orphan drug products in human clinical trials.
In 1985, inspired by the fact that, within two years of passage of the Orphan Drug Act, 54 orphan drugs were under development or already approved, Congress decided to extend the Act's authorization of research grants and expand its protection of marketing rights to all orphan drugs rather than just unpatentable ones.
Market conditions: provides an analysis of the orphan drug market, detailing the drivers for recent growth, prevalence and scientific advances
com/research/m9tbs3/us_orphan_drug) have announced the addition of the "US Orphan Drug Clinical Pipeline Insight 2014" report to their offering.
com/research/0944f17e/orphan_drugs_in_as) has announced the addition of the "Orphan Drugs in Asia: Guidelines and Regulatory Requirements to Help Orphan Drug Products Enter the Asian Market 2012" report to their offering.
Food and Drug Administration (FDA) has granted the company Orphan Drug designation for Saposin C, active ingredient in its proprietary drug BXQ-350 for the potential treatment of glioblastoma multiforme.
com/research/5q5tcr/global_orphan) has announced the addition of the "Concise Analysis of the International Orphan Drug Market Outlook 2018" report to their offering.